Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | CSK | P41240 | 1/20 | 0.48 |
| ▸ | SIK1 | P57059 | 1/20 | 0.48 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.48 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.48 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 11/20 | 0.46 |
| ▸ | NEK2 | P51955 | 2/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25425217 | 0.82 | FLT3 (0.50) | FGFR3KDRABL1PDGFRACSK | |
| SCHEMBL25425822 | 0.81 | FLT3 (0.45) | FGFR3KDRABL1PDGFRACSK | |
| SCHEMBL27030611 | 0.78 | FLT3 (0.49) | FGFR3KDRABL1PDGFRACSK | |
| SCHEMBL30775112 | 0.78 | FLT3 (0.49) | FGFR3KDRABL1PDGFRACSK | |
| SCHEMBL27030692 | 0.77 | FLT3 (0.47) | KDRABL1PDGFRACSKSIK1 | |
| SCHEMBL11925829 | 0.71 | KDR (0.68) | FGFR3KDRFLT3 | |
| SCHEMBL3322471 | 0.69 | FGFR3 (0.52) | FGFR3KDRABL1PDGFRACSK | |
| SCHEMBL3491326 | 0.67 | GSK3B (0.57) | ATR | |
| SCHEMBL31386948 | 0.66 | FLT3 (0.77) | KDRABL1PDGFRACSKSIK1 | |
| SCHEMBL27030592 | 0.66 | ABL1 (0.77) | ABL1PDGFRACSKSIK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024233967-A2 | SIK INHIBITORS TO TREAT CHRONIC KIDNEY DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | FGFR3 1163/4885KDR 1018/4885ABL1 474/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | FGFR3 1683/4885KDR 2083/4885ABL1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.